Literature DB >> 19357531

Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.

Jacob Joseph1, Michael J Pencina, Thomas J Wang, Laura Hayes, Geoffrey H Tofler, Paul Jacques, Jacob Selhub, Daniel Levy, Ralph B D'Agostino, Emelia J Benjamin, Ramachandran S Vasan.   

Abstract

OBJECTIVE: Hyperhomocysteinemia, neurohormonal activation, inflammation and altered fibrinolysis have been linked to atherothrombosis as well as to myocardial fibrosis and heart failure. Hence, we related a panel of biomarkers representing these pathways to plasma markers of collagen metabolism in a large community-based sample.
METHODS: We related nine biomarkers representing select biologic pathways (independent variables: C-reactive protein, B-type natriuretic peptide, N-terminal proatrial natriuretic peptide, aldosterone, renin, fibrinogen, D-dimer, plasminogen activator inhibitor-1 and homocysteine) to three plasma markers of collagen turnover [dependent variables, separate models for each: aminoterminal propeptide of type III collagen, tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-9 (present versus absent)] in 921 Framingham Heart study participants (mean age 57 years; 58% women). Participants were separated a priori into those with left ventricular end-diastolic dimensions and wall thickness below sex-specific median values (referent group) and either measure at least 90th sex-specific percentile ('remodeled' group). We used stepwise multivariable regression analysis adjusting for cardiovascular risk factors to relate the panel of systemic biomarkers to the three biomarkers of collagen metabolism.
RESULTS: Plasma homocysteine was positively related to all three markers of collagen metabolism in the remodeled group and to aminoterminal propeptide of type III collagen and tissue inhibitor of metalloproteinases-1 in the referent group. Plasminogen activator inhibitor-1 was positively related to aminoterminal propeptide of type III collagen and tissue inhibitor of metalloproteinases-1 in both groups, whereas the natriuretic peptides were associated positively with these collagen markers in the referent group.
CONCLUSION: In our large community-based sample, plasma homocysteine and plasminogen activator inhibitor-1 were positively related to circulating collagen biomarkers, consistent with experimental studies implicating these pathways in cardiovascular collagen turnover.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357531      PMCID: PMC2688088          DOI: 10.1097/HJH.0b013e328329fc20

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  34 in total

1.  Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats.

Authors:  Jacob Joseph; Lija Joseph; Nawal S Shekhawat; Sulochana Devi; Junru Wang; Russell B Melchert; Martin Hauer-Jensen; Richard H Kennedy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-01       Impact factor: 4.733

2.  Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Johan Sundstrom; Joanne M Murabito; Flora Sam; Wilson S Colucci; Peter W F Wilson
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

3.  Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.

Authors:  Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Peter W F Wilson; Ramachandran S Vasan
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

4.  Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study.

Authors:  Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Patrice Sutherland; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

5.  Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat.

Authors:  Ernest Walker; Jason Black; Cordel Parris; Elizabeth C Bryda; Silvestre Cansino; Lisa Hunt; Jean Chappell; Paulette Wehner; Mark Studeny; Gary L Wright
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

6.  Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction.

Authors:  Jarkko Magga; Mikko Puhakka; Seppo Hietakorpi; Kari Punnonen; Paavo Uusimaa; Juha Risteli; Olli Vuolteenaho; Heikki Ruskoaho; Keijo Peuhkurinen
Journal:  J Appl Physiol (1985)       Date:  2003-11-07

7.  Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction.

Authors:  Ramachandran S Vasan; Alexa Beiser; Ralph B D'Agostino; Daniel Levy; Jacob Selhub; Paul F Jacques; Irwin H Rosenberg; Peter W F Wilson
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

8.  Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed.

Authors:  J Orbe; L Fernandez; J A Rodríguez; G Rábago; M Belzunce; A Monasterio; C Roncal; José A Páramo
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

9.  Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study.

Authors:  Johan Sundström; Lisa Sullivan; Jacob Selhub; Emelia J Benjamin; Ralph B D'Agostino; Paul F Jacques; Irwin H Rosenberg; Daniel Levy; Peter W F Wilson; Ramachandran S Vasan
Journal:  Eur Heart J       Date:  2004-03       Impact factor: 29.983

10.  Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.

Authors:  Hideaki Moriwaki; April Stempien-Otero; Michal Kremen; Aaron E Cozen; David A Dichek
Journal:  Circ Res       Date:  2004-08-05       Impact factor: 17.367

View more
  7 in total

1.  Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality.

Authors:  Raghava S Velagaleti; Philimon Gona; Johan Sundström; Martin G Larson; Deborah Siwik; Wilson S Colucci; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-26       Impact factor: 8.311

2.  Association Between Inflammatory Markers and Myocardial Fibrosis.

Authors:  Mateus D Marques; Victor Nauffal; Bharath Ambale-Venkatesh; Henrique D Vasconcellos; Colin Wu; Hossein Bahrami; Russell P Tracy; Mary Cushman; David A Bluemke; João A C Lima
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

Review 3.  Quo vadis: whither homocysteine research?

Authors:  Jacob Joseph; Diane E Handy; Joseph Loscalzo
Journal:  Cardiovasc Toxicol       Date:  2009-05-30       Impact factor: 3.231

4.  Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.

Authors:  Sandra Geschka; Axel Kretschmer; Yuliya Sharkovska; Oleg V Evgenov; Bettina Lawrenz; Andreas Hucke; Berthold Hocher; Johannes-Peter Stasch
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

Review 5.  Methoxistasis: integrating the roles of homocysteine and folic acid in cardiovascular pathobiology.

Authors:  Jacob Joseph; Joseph Loscalzo
Journal:  Nutrients       Date:  2013-08-15       Impact factor: 5.717

6.  Homocysteine promotes cardiac fibrosis by regulating the Akt/FoxO3 pathway.

Authors:  Ying Shi; Lili Zhao; Yifei Zhang; Qin Qin; Hongliang Cong; Zhigang Guo
Journal:  Ann Transl Med       Date:  2021-12

7.  Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function.

Authors:  Hui Zhi; Ivan Luptak; Gaurav Alreja; Jianru Shi; Jian Guan; Nicole Metes-Kosik; Jacob Joseph
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.